Optimal treatment intensity in children with Down syndrome and myeloid leukaemia: Data from 56 children treated on NOPHO-AML protocols and a review of the literature

Annals of Hematology

Volumn 85, Issue 5, 2006, Pages 275-280

  Abildgaard, Lotte ^a   Ellebæk, Eva ^a   Gustafsson, Göran ^b   Abrahamsson, Jonas ^c   Hovi, Liisa ^d   Jonmundsson, Gudmundur ^e   Zeller, Bernward ^f   Hasle, Henrik ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c QUEEN SILVIA CHILDREN'S HOSPITAL   (Sweden)

^d UNIVERSITY OF HELSINKI   (Finland)

^e Landspitalinn ^*  (Iceland)

^f OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

AML; Children; Down syndrome; Therapy

Indexed keywords

ANTHRACYCLINE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; MITOXANTRONE; TIOGUANINE;

ACUTE GRANULOCYTIC LEUKEMIA; CANCER SURVIVAL; CARDIOTOXICITY; CHILD; CONTINUOUS INFUSION; CONTROLLED STUDY; CYTOPENIA; DISEASE ASSOCIATION; DOWN SYNDROME; DRUG DOSE REGIMEN; DRUG FATALITY; HEART FAILURE; HUMAN; LEUKEMIA RELAPSE; MAJOR CLINICAL STUDY; PNEUMONIA; PRIORITY JOURNAL; RESPIRATORY DISTRESS; REVIEW;

ANTHRACYCLINES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD, PRESCHOOL; CYTARABINE; DISEASE-FREE SURVIVAL; DOWN SYNDROME; HUMANS; LEUKEMIA, MYELOID; MALE; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 33646676254     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-005-0045-5     Document Type: Review

References (19)

1. Gurbuxani S, Vyas P, Crispino JD (2004) Recent insights into the mechanisms of myeloid leukemogenesis in Down syndrome. Blood 103:399-406
2. Hasle H, Niemeyer CM, Chessells JM, Baumann I, Bennett JM, Kerndrup G, Head DR (2003) A pediatric approach to the WHO classification of myelodysplastic and myeloproliferative diseases. Leukemia 17:277-282
3. Gamis AS, Woods WG, Alonzo TA, Buxton A, Lange B, Barnard DR, Gold S, Smith FO (2003) Increased age at diagnosis has a significantly negative effect on outcome in children with Down syndrome and acute myeloid leukemia: A report from the children's cancer group study 2891. J Clin Oncol 21:3415-3422
4. Ravindranath Y (2003) Down syndrome and acute myeloid leukemia: The paradox of increased risk for leukemia and heightened sensitivity to chemotherapy. J Clin Oncol 21:3385-3387
5. Creutzig U, Reinhardt D, Diekamp S, Dworzak M, Stary J, Zimmermann M (2005) AML patients with Down syndrome have a high cure rate with AML-BFM therapy with reduced dose intensity. Leukemia 19:1355-1360
6. Lie SO, Abrahamsson J, Clausen N, Forestier E, Hasle H, Hovi L, Jonmundsson G, Mellander L, Gustafsson G (2003) Treatment stratification based on initial in vivo response in acute myeloid leukaemia in children without Down syndrome. Results of NOPHO-AML trials. Br J Haematol 122:217-225
7. Creutzig U, Ritter J, Zimmermann M, Hermann J, Gadner H, Sawatzki DB, Niemeyer CM, Schwabe D, Selle B, Boos J, Kuhl J, Feldges A (2001) Idarubicin improves blast cell clearance during induction therapy in children with AML: Results of study AML-BFM 93. AML-BFM Study Group. Leukemia 15:348-354
8. Webb DK, Harrison G, Stevens RF, Gibson BG, Hann IM, Wheatley K (2001) Relationships between age at diagnosis, clinical features, and outcome of therapy in children treated in the Medical Research Council AML 10 and 12 trials for acute myeloid leukemia. Blood 98:1714-1720
9. Taub JW, Huang X, Matherly LH, Stout ML, Buck SA, Massey GV, Becton DL, Chang MN, Weinstein HJ, Ravindranath Y (1999) Expression of chromosome 21-localized genes in acute myeloid leukemia: Differences between Down syndrome and non-Down syndrome blast cells and relationship to in vitro sensitivity to cytosine arabinoside and daunorubicin. Blood 94:1393-1400
10. Frost BM, Gustafsson G, Larsson R, Nygren P, Lönnerholm G (2000) Cellular cytotoxic drug sensitivity in children with acute leukemia and Down's syndrome: An explanation to differences in clinical outcome? Leukemia 14:943-944
11. Zwaan CM, Kaspers GJ, Pieters R, Hahlen K, Janka-Schaub GE, Van Zantwijk CH, Huismans DR, de Vries E, Rots MG, Peters GJ, Jansen G, Creutzig U, Veerman AJ (2002) Different drug sensitivity profiles of acute myeloid and lymphoblastic leukemia and normal peripheral blood mononuclear cells in children with and without Down syndrome. Blood 99:245-251
12. Hasle H (2001) Pattern of malignant disorders in individuals with Down's syndrome. Lancet Oncol 62:429-436
13. Creutzig U, Ritter J, Vormoor J, Ludwig WD, Niemeyer C, Reinisch I, Stollmann Gibbels B, Zimmermann M, Harbott J (1996) Myelodysplasia and acute myelogenous leukemia in Down's syndrome. A report of 40 children of the AML-BFM Study Group. Leukemia 10:1677-1686
14. Craze JL, Harrison G, Wheatley K, Hann IM, Chessells JM (1999) Improved survival of acute myeloid leukaemia in Down's syndrome. Arch Dis Child 81:32-37
15. Lange BJ, Kobrinsky N, Barnard DR, Arthur DC, Buckley JD, Howells WB, Gold S, Sanders J, Neudorf S, Smith FO, Woods WG (1998) Distinctive demography, biology, and outcome of acute myeloid leukemia and myelodysplastic syndrome in children with Down syndrome: Children's Cancer Group studies 2861 and 2891. Blood 91:608-615
16. Zeller B, Gustafsson G, Forestier E, Abrahamsson J, Clausen N, Heldrup J, Hovi L, Jonmundsson G, Lie SO, Glomstein A, Hasle H (2005) Acute leukaemia in children with Down syndrome: A population-based Nordic study. Br J Haematol 128:797-804
17. Ravindranath Y, Abella E, Krischer JP, Wiley J, Inoue S, Harris M, Chauvenet A, Alvarado CS, Dubowy R, Ritchey AK, Land V, Steuber CP, Weinstein H (1992) Acute myeloid leukemia (AML) in Down's syndrome is highly responsive to chemotherapy: Experience on Pediatric Oncology Group AML Study 8498. Blood 80:2210-2214
18. Kojima S, Sako M, Kato K, Hosoi G, Sato T, Ohara A, Koike K, Okimoto Y, Nishimura S, Akiyama Y, Yoshikawa T, Ishii E, Okamura J, Yazaki M, Hayashi Y, Eguchi M, Tsukimoto I, Ueda K (2000) An effective chemotherapeutic regimen for acute myeloid leukemia and myelodysplastic syndrome in children with Down's syndrome. Leukemia 14:786-791
19. The AML Collaborative group (1998) A systematic collaborative overview of randomized trials comparing idarubicin with daunorubicin (or other anthracyclines) as induction therapy for acute myeloid leukaemia. Br J Haematol 103:100-109